Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 10;17(5):1023-1032.
doi: 10.1016/j.stemcr.2022.04.002. Epub 2022 Apr 28.

Investigating the feasibility and ethical implications of phenotypic screening using stem cell-derived tissue models to detect and manage disease

Alexander R Harris  1 , Mary Jean Walker  2 , Frederic Gilbert  3 , Patrick McGivern  4
Affiliations
Review

Investigating the feasibility and ethical implications of phenotypic screening using stem cell-derived tissue models to detect and manage disease

Alexander R Harris et al. Stem Cell Reports. .

Abstract

Stem-cell-derived tissue models generated from sick people are being used to understand human development and disease, drug development, and drug screening. However, it is possible to detect disease phenotypes before a patient displays symptoms, allowing for their use as a disease screening tool. This raises numerous issues, some of which can be addressed using similar approaches from genetic screenings, while others are unique. One issue is the relationship between disease disposition, biomarker detection, and patient symptoms and how tissue models could be used to define disease. Other issues include decisions of when to screen, what diseases to screen for, and what treatment options should be offered.

Keywords: disease definition; ethics; phenotype; prenatal; stem cell; tissue model.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no competing interests.

Figures

Figure 1
Figure 1
Potential method for disease screening using stem-cell-derived tissue models
See this image and copyright information in PMC

References

    1. Adeyemo A., Balaconis M.K., Darnes D.R., Fatumo S., Granados Moreno P., Hodonsky C.J., Inouye M., Kanai M., Kato K., Knoppers B.M., et al. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat. Med. 2021;27:1876–1884. - PubMed
    1. Amin N.D., Paşca S.P. Building models of brain disorders with three-dimensional organoids. Neuron. 2018;100:389–405. - PubMed
    1. Aro A.R., Hakonen A., Hietala M., Lönnqvist J., Niemelä P., Peltonen L., Aula P. Acceptance of genetic testing in a general population: age, education and gender differences. Patient Educ. Couns. 1997;32:41–49. - PubMed
    1. Barker-Haliski M.L., Johnson K., Billingsley P., Huff J., Handy L.J., Khaleel R., Lu Z., Mau M.J., Pruess T.H., Rueda C., et al. Validation of a preclinical drug screening platform for pharmacoresistant epilepsy. Neurochem. Res. 2017;42:1904–1918. - PMC - PubMed
    1. Bedson J., McCarney R., Croft P. Labelling chronic illness in primary care: a good or a bad thing? Br. J. Gen. Pract. 2004;54:932–938. - PMC - PubMed